Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.15 USD | -0.80% | -6.55% | -4.01% |
May. 21 | QIAGEN NV : Berenberg maintains a Buy rating | ZD |
May. 15 | Qiagen's Updated Clinical Decision Support Platform Secures EU Certification | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With a 2024 P/E ratio at 23.86 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.01% | 9.65B | A | ||
+64.39% | 62.59B | B- | ||
-2.11% | 41.18B | B | ||
+44.76% | 40.29B | A | ||
-8.93% | 27.9B | C | ||
+12.34% | 26.21B | B- | ||
-21.75% | 19.09B | B | ||
+3.79% | 13.08B | B+ | ||
+25.56% | 12.26B | B+ | ||
+27.19% | 12.05B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- QGEN Stock
- Ratings Qiagen N.V.